Cynanchum atratum Alleviates Non-Alcoholic Fatty Liver by Balancing Lipogenesis and Fatty Acid Oxidation in a High-Fat, High-Fructose Diet Mice Model

Abstract

Cynanchum atratum, a medicinal herb, is traditionally used as an antidote, diuretic, and antipyretic in eastern Asia. The current study aimed to investigate the anti-fatty liver capacity of the ethanol extract of Cynanchum atratum (CAE) using a 10-week high-fat, high-fructose diet mouse model. A six-week treatment of CAE (from the fifth week) significantly attenuated the weights of the body, liver, and mesenteric fat without a change in diet intake. CAE also considerably restored the alterations of serum aminotransferases and free fatty acid, fasting blood glucose, serum and hepatic triglyceride, and total cholesterol, as well as platelet and leukocyte counts. Meanwhile, CAE ameliorated hepatic injury and lipid accumulation, as evidenced by histopathological and immunofluorescence observations. Additionally, CAE significantly lowered the elevation of hepatic TNF-α, the TNF-α/IL-10 ratio, fecal endotoxins, and the abundance of Gram-negative bacteria. Hepatic lipogenesis and β-oxidation-related proteins and gene expression, including PPAR-α, SREBP-1, SIRT1, FAS, CTP1, etc., were normalized markedly by CAE. In particular, the AMPK, a central regulator of energy metabolism, was phosphorylated by CAE at an even higher rate than metformin. Overall, CAE exerts anti-hepatic steatosis effects by reducing lipogenesis and enhancing fatty acid oxidation. Consequently, Cynanchum atratum is expected to be a promising candidate for treating chronic metabolic diseases.

The effect of lipid metabolism disorder on the immune microenvironment in Xinjiang patients with hyperuricemia using Multi-Omics analysis

“…Glycerol, fatty acids, and phospholipids are vital components of glycerophospholipids, among which dietary fatty acids can promote the oxidation of fatty acids (FAO) in mitochondria, accelerate the production of TG in fat droplets, and provide more energy to liver cells [24] . Therefore, fat accumulation in the liver can be blocked by the oxidation of fatty acids, resulting in a disorder of lipid metabolism [25] . However, inhibition of mitochondrial FAO will affect the expression of key regulatory factors in the energy metabolism pathway and modify the level of intracellular metabolites, thus reshaping intracellular energy metabolism homeostasis [26] .…”

Bacillus subtilis-Fermented Amomum xanthioides Ameliorates Metabolic-Syndrome-Like Pathological Conditions in Long-Term HFHFD-Fed Mice

“…In modern society, metabolic disturbance, commonly referred to as comorbidity with NAFLD, hyperlipidemia, obesity, and Type 2 diabetes, has become increasingly serious worldwide [ 1 , 24 ]. It has already been proven that a long-term HFHFD treatment is a reliable approach for establishing an animal model of chronic metabolic disorders [ 25 , 26 ]. Unlike the previous HFD-only model, animal models fed with a combination of an HFD and a high-fructose diet have been more frequently applied due to the very humanlike clinical symptoms exhibited [ 27 ].…”

Dose- and time-dependent manners of moxifloxacin induced liver injury by targeted metabolomics study

“…The liver plays central role in lipid metabolism by absorbing serum free fatty acids, and manufacturing, storing, and transporting lipid metabolites (Musso et al, 2009). Elevated fatty acid levels in the liver can cause hepatocyte injury via the formation of various toxic metabolites, such as eicosanoids, ceramide, diacylglycerols, and lysophosphatidylcholine (Bessone et al, 2019;Wang et al, 2021). Some resent studiers have found that fatty acid accumulation in the liver tissue may be an important cause of hepatotoxicity for patients with metabolic syndrome (McClain et al, 2007;Yamaguchi et al, 2007).…”